Israel Englander’s Neurocrine Biosciences NBIX Stock Holding History

Israel Englander’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,700	Closed	-$7.12M	–	6308
2025 Q3	$7.12M	Buy	+50,700	New	+$6.87M	﹤0.01%	2744
2025 Q1	–	Sell	-8,800	Closed	-$1.2M	–	6219
2024 Q4	$1.2M	Sell	8,800 -9,900	-53%	-$1.22M	﹤0.01%	4048
2024 Q3	$2.15M	Buy	+18,700	New	+$2.56M	﹤0.01%	3637
2023 Q4	–	Sell	-15,000	Closed	-$1.69M	–	6369
2023 Q3	$1.69M	Buy	+15,000	New	+$1.58M	﹤0.01%	3718
2017 Q1	–	Sell	-200,000	Closed	-$7.74M	–	3726
2016 Q4	$7.74M	Buy	+200,000	New	+$9.05M	0.02%	1067
2015 Q2	–	Sell	-100,000	Closed	-$3.97M	–	3655
2015 Q1	$3.97M	Hold	100,000	–	–	0.01%	1545
2014 Q4	$2.23M	Buy	+100,000	New	+$1.89M	﹤0.01%	1896

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's NBIX Position: Q2 2026 in Review

Israel Englander reduced its Neurocrine Biosciences (NBIX) stake by 99% in Q2 2026, selling an estimated $183M and leaving 11,585 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3841.

Israel Englander first reported a position in NBIX in Q2 2013 and has held it in 49 quarters since. The position peaked at $164M in Q1 2026. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Israel Englander held 11,585 shares of Neurocrine Biosciences worth $1.95M as of Q2 2026.
Israel Englander sold 1,235,862 Neurocrine Biosciences shares in Q2 2026, an estimated $183M.
Neurocrine Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3841 holding.
Israel Englander first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 49 quarters since.
Israel Englander's Neurocrine Biosciences position peaked at $164M in Q1 2026.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.